NEWPORT BEACH, Calif., June 25, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Roth Capital Partners (“Roth”), www.roth.com, is set to virtually present the Roth Virtual Healthcare Private Company Forum on June 28th, 2021.
This event will consist of Virtual Panels on Emerging Therapeutics and select Fireside Chats with Roth Research Analysts. This format will provide an opportunity for C-level executives representing established private healthcare companies in the Biotechnology, Pharmaceuticals and Medical Technologies verticals to tell their stories.
“We are excited to host our Virtual Healthcare Private Company Forum for private companies. As the event continues to grow, we are bringing together a broader range of private healthcare companies, from across the US and beyond, to tell their stories,” said James Antonopoulos, Managing Director & Head of Healthcare Investment Banking at Roth. “This event is another example of Roth’s continued leadership in supporting the growth of healthcare companies, including biotechnology, specialty pharmaceuticals, medical devices & diagnostics.”
Since 2010, Roth has been involved in over 530 transactions for its Healthcare clients with a total transaction value of over $24 billion. (Source: Roth Capital Partners | 06.24.21)
For more information and event registration, please see www.roth.com/healthcareprivatecompany, or contact your Roth event representative at (949) 720-5700 or registration@roth.com.
Event Agenda (All times in ET):
MONDAY | JUNE 28, 2021 | Full details: https://ibn.fm/RothVirtualHealthForumAgenda
8:00 am Cullgen Inc. – Fireside Chat
8:20 am M6P Therapeutics – Fireside Chat
8:40 am Ryvu Therapeutics – Fireside Chat
9:00 am Novel Approaches to Tumor Eradication – Panel with Enterome & Invectys
10:00 am Renaissance Bioscience – Fireside Chat
10:20 am Aruna Bio – Fireside Chat
10:40 am Dyve Biosciences – Fireside Chat
11:00 am Next Wave of Psychedelic Drug Developers – Panel with Diamond Therapeutics, Field Trip Health (FTRP.TO), Mydecine (OTC: MYCOF) & Small Pharma (DMT.V)
12:00 pm Natural Killer Cell Approaches to Eradicate Tumors – Panel with Alloplex Biotherapeutics, Alphageneron, Cytovia & NKGen Biotech
1:00 pm Active Motif - Fireside Chat
1:20 pm Intensity Therapeutics – Fireside Chat
1:40 pm Fibralign – Fireside Chat
2:00 pm Reva Medical – Fireside Chat
Participating Company List:
| Company Name | Company Website (URL) |
| Active Motif | https://www.activemotif.com/ |
| Alloplex Biotherapeutics | https://alloplexbio.com/ |
| Alphageneron | https://alphageneron.com/ |
| Aruna Bio | https://www.arunabio.com/ |
| Cullgen Inc. | https://www.cullgen.com/ |
| Cytovia | https://www.cytoviatx.com/ |
| Diamond Therapeutics | https://www.diamondthera.com/ |
| Dyve Biosciences | https://dyvebio.com/ |
| Enterome | https://www.enterome.com/ |
| Fibralign | https://www.fibralignbio.com/ |
| Field Trip Health (FTRP.TO) | https://www.fieldtriphealth.com/ |
| Intensity Therapeutics | https://intensitytherapeutics.com/ |
| Invectys Inc. | https://www.invectys.com/ |
| M6P Therapeutics | https://m6ptherapeutics.com/ |
| Mydecine (OTC: MYCOF) | https://www.mydecine.com/ |
| NKGen Biotech, Inc. | https://nkgenbiotech.com/ |
| Renaissance Bioscience | https://renaissancebioscience.com/ |
| Reva Medical | https://www.revamedical.com/ |
| Ryvu Therapeutics | https://ryvu.com/ |
| Small Pharma (DMT.V) | https://www.smallpharma.co.uk/ |
Subject to Change | As of 06/22/2021
Event Media Sponsor:
| Company Name | Company Website (URL) |
| InvestorBrandNetwork | https://www.investorbrandnetwork.com/ |
About Roth Capital Partners, LLC:
Roth Capital Partners, LLC (“Roth”) is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, Roth provides capital raising, M&A advisory, analytical research, trading, market-making services, and corporate access. Headquartered in Newport Beach, CA, Roth is privately-held, employee owned, and maintains offices throughout the U.S. For more information on Roth, please visit www.roth.com.
Investor Contact:
Roth Capital Partners
Isabel Mattson-Pain
Director of Marketing & Corporate Access
Imattson-pain@roth.com
949.720.7117
Media Contact:
InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com